Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Astellas Pharma Europe Ltd - Putting the patient first: Considering treatment choice and maximising quality of life in mHSPC

The importance of first-line treatment choice in patients with mHSPC

Date

22 Oct 2023

Session

Astellas Pharma Europe Ltd - Putting the patient first: Considering treatment choice and maximising quality of life in mHSPC

Topics

Tumour Site

Prostate Cancer

Presenters

All Speakers

Authors

H.A. Payne1, C. Sweeney2, J. Puente3, A. Speakers4

Author affiliations

  • 1 Oncology, University College London Hospitals NHS Foundation Trust, NW1 2BU - London/GB
  • 2 South Australian Immunogenomics Cancer Institute, The University of Adelaide, 5005 - Adelaide/AU
  • 3 Dept. Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 4 ESMO - European Society for Medical Oncology, GX11 1AA - Lugano/CH

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.